Imugene Financials
| IMU Stock | 0.04 0 2.56% |
Operating Margin 22.8569 | EPS Estimate Current Year (0.02) | Return On Equity (0.97) |
Imugene | Select Account or Indicator |
Understanding current and past Imugene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Imugene's financial statements are interrelated, with each one affecting the others. For example, an increase in Imugene's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Imugene's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Imugene. Check Imugene's Beneish M Score to see the likelihood of Imugene's management manipulating its earnings.
Imugene Stock Summary
Imugene competes with Clime Investment, Viva Leisure, Kip McGrath, REGAL ASIAN, and BKI Investment. Imugene is entity of Australia. It is traded as Stock on AU exchange.| Foreign Associate | Germany |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | Australia Stock View All |
| Exchange | Australian Securities Exchange |
| ISIN | AU000000IMU9 |
| Business Address | 4-6 Bligh Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.imugene.com |
| Phone | 61 2 9423 0881 |
You should never invest in Imugene without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Imugene Stock, because this is throwing your money away. Analyzing the key information contained in Imugene's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Imugene Key Financial Ratios
Imugene's financial ratios allow both analysts and investors to convert raw data from Imugene's financial statements into concise, actionable information that can be used to evaluate the performance of Imugene over time and compare it to other companies across industries.| Revenue | 4.97 M | ||||
| Gross Profit | 11.78 M | ||||
| EBITDA | (147.98 M) | ||||
| Net Income | (149.68 M) | ||||
| Cash And Equivalents | 49.54 M |
Imugene Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 65.2M | 71.8M | 147.6M | 197.1M | 151.4M | 159.0M | |
| Other Current Liab | 1.8M | 3.6M | 2.7M | 3.6M | 22.4M | 23.5M | |
| Net Debt | (30.0M) | (29.2M) | (99.2M) | (152.6M) | (91.6M) | (87.0M) | |
| Retained Earnings | (47.3M) | (65.7M) | (103.5M) | (141.4M) | (289.8M) | (275.3M) | |
| Accounts Payable | 1.0M | 759.7K | 4.5M | 2.3M | 6.0M | 6.3M | |
| Cash | 30.1M | 29.5M | 99.9M | 153.2M | 93.1M | 97.8M | |
| Net Receivables | 4.2M | 6.7M | 12.8M | 12.1M | 12.6M | 13.2M | |
| Total Liab | 5.4M | 6.8M | 8.9M | 7.4M | 33.1M | 34.8M | |
| Total Current Assets | 34.5M | 36.3M | 113.8M | 165.7M | 113.0M | 118.7M | |
| Short Term Debt | 60.9K | 106.0K | 184.2K | 191.1K | 912.5K | 958.1K | |
| Intangible Assets | 30.5M | 34.9M | 32.7M | 30.5M | 34.1M | 35.8M | |
| Common Stock | 92.8M | 113.1M | 230.8M | 314.4M | 370.3M | 388.8M | |
| Other Liab | 2.5M | 2.2M | 987.1K | 990.6K | 1.1M | 1.1M | |
| Net Tangible Assets | 29.3M | 30.1M | 106.0M | 159.1M | 183.0M | 192.2M | |
| Other Current Assets | 194.1K | 170.1K | 1.1M | 401.6K | 5.9M | 6.2M | |
| Long Term Debt Total | 8.4K | 165.0K | 489.3K | 362.4K | 326.2K | 462.4K | |
| Net Invested Capital | 59.8M | 65.0M | 138.7M | 188.4M | 118.3M | 85.8M |
Imugene Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 5.0K | 5.0K | 13.6K | 27.5K | 478.4K | 502.3K | |
| Operating Income | (14.9M) | (25.7M) | (50.7M) | (51.3M) | (140.9M) | (133.9M) | |
| Ebit | (14.6M) | (25.7M) | (50.5M) | (49.6M) | (153.8M) | (146.1M) | |
| Ebitda | (14.6M) | (23.7M) | (48.1M) | (47.4M) | (148.0M) | (140.6M) | |
| Income Before Tax | (14.6M) | (25.7M) | (50.5M) | (49.7M) | (154.3M) | (146.6M) | |
| Net Income | (10.5M) | (18.5M) | (37.9M) | (37.9M) | (149.7M) | (142.2M) | |
| Income Tax Expense | (4.1M) | (7.2M) | (12.6M) | (11.7M) | (4.6M) | (4.4M) | |
| Total Revenue | 4.1M | 7.2M | 13.0M | 11.8M | 13.5M | 14.2M | |
| Gross Profit | 4.1M | 5.3M | 10.6M | 9.6M | (5.8M) | (5.5M) | |
| Research Development | 9.4M | 15.4M | 36.6M | 30.9M | 86.9M | 91.2M | |
| Cost Of Revenue | 82.5K | 2.0M | 2.4M | 2.2M | 5.8M | 6.1M | |
| Interest Income | 297.2K | 126.6K | 192.2K | 1.9M | 4.5M | 4.7M | |
| Net Interest Income | 297.2K | 10.5K | 71.9K | 1.9M | 4.0M | 4.2M |
Imugene Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 11.1M | (619.7K) | 70.4M | 53.3M | (60.0M) | (57.0M) | |
| Free Cash Flow | (11.6M) | (18.6M) | (30.9M) | (29.8M) | (106.8M) | (101.4M) | |
| Depreciation | 82.5K | 2.0M | 2.4M | 2.2M | 5.8M | 6.1M | |
| Other Non Cash Items | 2.5M | 12.1M | 17.1M | 10.2M | 52.4M | 55.0M | |
| Capital Expenditures | 128.4K | 1.5M | 5.4M | 257.7K | 13.1M | 13.7M | |
| Net Income | (10.5M) | (18.5M) | (37.9M) | (37.9M) | (149.7M) | (142.2M) | |
| End Period Cash Flow | 30.1M | 29.5M | 99.9M | 153.2M | 93.1M | 97.8M | |
| Change To Inventory | 987.1K | (51.5K) | (1.9M) | 676.9K | 609.2K | 639.7K | |
| Investments | (30.6K) | (34.6K) | (137.2K) | 1.9M | (7.3M) | (6.9M) | |
| Net Borrowings | (53.6K) | 67.9K | (10.8K) | (147.4K) | (132.7K) | (126.0K) | |
| Change To Netincome | 1.0M | 5.6M | 8.8M | 3.6M | 4.2M | 4.4M |
Imugene Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Imugene's current stock value. Our valuation model uses many indicators to compare Imugene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Imugene competition to find correlations between indicators driving Imugene's intrinsic value. More Info.Imugene is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Imugene's earnings, one of the primary drivers of an investment's value.Imugene Systematic Risk
Imugene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Imugene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Imugene correlated with the market. If Beta is less than 0 Imugene generally moves in the opposite direction as compared to the market. If Imugene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Imugene is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Imugene is generally in the same direction as the market. If Beta > 1 Imugene moves generally in the same direction as, but more than the movement of the benchmark.
Imugene Total Assets Over Time
Imugene December 11, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Imugene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Imugene. We use our internally-developed statistical techniques to arrive at the intrinsic value of Imugene based on widely used predictive technical indicators. In general, we focus on analyzing Imugene Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Imugene's daily price indicators and compare them against related drivers.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 17.67 | |||
| Value At Risk | (7.50) | |||
| Potential Upside | 6.25 |
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.